Abstract
The advent of CRISPR-Cas9 gene-editing technology has revolutionized pharmaceutical research, offering unprecedented potential for targeted therapies and the development of novel drugs. By enabling precise modifications in the DNA of living organisms, CRISPR-Cas9 facilitates the study of gene function, the identification of disease-associated genes, and the development of gene-based treatments. This article explores the applications of CRISPR-Cas9 in pharmaceutical research, including drug discovery, genetic disease modeling, and gene therapy. Additionally, it discusses the challenges, ethical considerations, and future directions of CRISPR-based therapeutics in the pharmaceutical industry.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.